APSR2026-1075

 
Late-Breaking
Submitted
Oral Presentation
AO36-006
 
 
https://storage.unitedwebnetwork.com/files/1285/1000040-46903-A036-006 Economic Burden of Drug-Resistant Versus Drug-Susceptible Tuberculosis in Malaysia_440975.pptx
Format: PPTX Only
 
Format: PDF Only
06. Tuberculosis
11

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Aisya Natasya Musa * Universiti Teknologi MARA Respiratory Unit, Faculty of Medicine Sungai Buloh, Selangor Malaysia Universiti Teknologi MARA Respiratory Service Centre, Hospital Al-Sultan Abdullah Puncak Alam, Selangor Malaysia
Aidalina Mahmud - Universiti Putra Malaysia (UPM) Faculty of Medicine and Health Sciences Serdang Malaysia
Siti Hafsah Abdul Halim - Disease Control Division, Ministry of Health TB & Leprosy Control Sector Putrajaya Malaysia
Yen Shen Wong - Universiti Teknologi MARA Respiratory Unit, Faculty of Medicine Sungai Buloh, Selangor Malaysia Universiti Teknologi MARA Respiratory Service Centre, Hospital Al-Sultan Abdullah Puncak Alam, Selangor Malaysia
Suzana Mohd Hashim - Disease Control Division, Ministry of Health TB & Leprosy Control Sector Putrajaya Malaysia
Shazelin Alipitchay - Disease Control Division, Ministry of Health TB & Leprosy Control Sector Putrajaya Malaysia
Hakimah Yusop - Disease Control Division, Ministry of Health TB & Leprosy Control Sector Putrajaya Malaysia
Mohd Fadhli Mohd Fauzi - Ministry of Health Public Health Medicine Putrajaya Malaysia
Chin Mun Wong - Jabatan Kesihatan Negeri Pahang Public Health Medicine Pahang Malaysia
Mugilan Ganason - Disease Control Division, Ministry of Health TB & Leprosy Control Sector Putrajaya Malaysia
Sharifa Ezat Wan Puteh - Universiti Kebangsaan Malaysia Department of Community Health Cheras Malaysia
 
 
 
 
Presenting Author Details
Aisya Natasya
Musa
aisyanatasya@gmail.com
+60178857113
41-50
Malaysia
Original Research
Economic Burden Of Drug-Resistant Versus Drug-Susceptible Tuberculosis In Malaysia
Maximum 25 words
Abstract Content
Drug-resistant tuberculosis (DR-TB) requires longer and more complex treatment than drug-susceptible tuberculosis (DS-TB), potentially resulting in greater economic burden on affected households. The aim of this study is to compare costs, income loss, time loss, and financial hardship between households affected by DR-TB and DS-TB in Malaysia.
This study is a national facility based survey. 786 patients were recruited involving 703 DS-TB and 83 DR-TB patients. Patient-incurred direct medical, direct non-medical, and indirect costs were measured from symptom onset until completion of treatment. Catastrophic costs were assessed using the WHO-recommended threshold of 20% of annual pre-TB household income.
DR-TB households experienced substantially greater economic burden than DS-TB households. Median total TB episode cost was RM11,118 among DR-TB patients compared with RM2,949 among DS-TB patients, representing nearly a four-fold difference. Catastrophic costs affected 58% of DR-TB households versus 35% of DS-TB households. Median time lost due to care-seeking and treatment was 368 hours (approximately 46 working days) among DR-TB patients compared with 159 hours (approximately 20 working days) among DS-TB patients. Hospitalisation was more common among DR-TB patients (43.4% versus 15.1%), contributing significantly to productivity losses. DR-TB patients also experienced greater reductions in income, higher indirect costs, and higher direct non-medical expenditures. Social consequences were more pronounced among DR-TB households, including greater job interruption (41.0% versus 27.3%), food insecurity (19.3% versus 6.4%), and reliance on coping strategies such as borrowing money or selling assets (22.9% versus 14.4%).
DR-TB imposes a disproportionately high economic burden compared with DS-TB, driven primarily by prolonged treatment, hospitalisation, and income loss. Targeted financial assistance and enhanced social protection for DR-TB patients should be prioritised to reduce catastrophic costs and improve treatment outcomes.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
DRTB, DSTB, Cost
maximum 3 keywords and no abbreviations, separated by commas
WHO Grant received for this study
286